Important considerations for the referral of patients with severe aortic stenosis

In this recorded webinar hear from leading cardiologist Dr. Shrilla Banerjee on:

  • What sort of service does she want for her patients
  • Which patients should be referred
  • The ideal patient pathway
  • Barriers to the adoption of TAVI
  • A new tool for the referral process that includes assessment of frailty

Speaker

DrShrillaBanerjee.jpg
Dr. Shrilla Banerjee
Surrey and Sussex Healthcare NHS Trust

In the new publication from GIRFT (Get It Right First Time) “to ensure that serial referrals are avoided and that all relevant treatment options are considered, each tertiary centre should have a single point of entry into a pathway for the assessment of patients referred for consideration of intervention for severe aortic valve disease and another for the assessment of severe mitral/tricuspid disease. Referrals should be made to the relevant heart team rather than to an individual cardiologist or surgeon¹.

Hear more from Dr. Shrilla Banerjee on her view of the perfect referral pathway.
Play Video

Check our latest articles

https://1acvlp2qw4ys2fyruq3xmc93-wpengine.netdna-ssl.com/wp-content/uploads/2022/04/73031724-001_GettyImages-1294678917_630x700px@72dpi.jpg
Challenges in treating patients with asymptomatic severe aortic stenosis (sAS)
May 2022 Read more
The 2021 ESC/EACTS guidelines recommend all* sAS patients with severe aortic stenosis are referred to the Heart Team1
Feb 2022 Read more

Stay informed with our newsletter

Our monthly updates provide you the latest developments in TAVI and aortic stenosis.     Read more

References

  • 1Clarke, S and Ray, S (2021) GIRFT Programme National Specialty Report, Cardiology pg 38. Available at: https://www.gettingitrightfirsttime.co.uk/wp-content/uploads/2021/02/Cardiology-10-03i-EMBARGOED.pdf

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, PARTNER, PARTNER 3, SAPIEN, and SAPIEN 3 are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

 

©2022 Edwards Lifesciences Corporation. All rights reserved. PP–EU-3409 v1.0

Content relating to Tavi.today is intended for healthcare professionals. Click OK to confirm you are a healthcare professional and proceed.
Skip to content